A Strong Contender for the Next Nobel Prize

The startup Iambic has made a breakthrough that surpasses Google DeepMind’s AlphaFold. While AlphaFold, the AI system developed by Google DeepMind, recently earned a Nobel Prize in Chemistry for predicting the 3D structure of how molecules bind to target proteins, this is just the beginning. It’s impressive but not enough to drastically reduce the time (10-15 years) and costs ($1-2.6 billion per drug) required to bring new medicines to market.

Iambic has taken it a step further by developing an AI model that predicts, with remarkable accuracy, how well a human body will absorb a specific drug candidate. The predictions are validated against real-world data, making it a promising tool for pharmaceutical development.

The success of a drug candidate depends on several key properties—pharmacokinetics, efficacy, and toxicity. These are exactly the factors predicted by Iambic’s AI-powered drug discovery platform called Enchant, which boasts a predictive accuracy of 0.74, compared to just 0.58 achieved by previous models.

The Enchant model could potentially cut the costs of drug development in half, allowing pharmaceutical companies to assess a drug’s potential success at the earliest stages of research.

To understand the significance of Iambic’s breakthrough, consider the vast competition in the “AI in Biomedicine” sector, where more than 8,600 companies are racing to unlock the next major innovation (as shown in the chart above). In the sub-segment of “AI-based Analytics Platforms for Drug Development” alone, the number of companies has grown fourfold in the last three years, now standing at 950 competitors (see the chart below).

#AI #DeepPharma #DrugDiscovery #Biotech #Pharmacology #AlphaFold
#science

🩸 Artificial Blood That Saves Lives

A groundbreaking artificial blood product called ErythroMer can be stored for years and transfused to any patient — regardless of blood type — directly at the scene of an emergency. Developed in the U.S., this powder-based blood substitute only needs to be mixed with sterile water before use.

ErythroMer is made from hemoglobin extracted from expired donor blood, encapsulated in lipid nanoparticles that mimic red blood cells. This innovation could revolutionize emergency medicine and dramatically improve survival rates in critical situations. ✨

#Biotech #EmergencyMedicine #Innovation #ArtificialBlood
@Science

💊 MIT researchers use AI to fight drug-resistant bacteria

Scientists at MIT are turning to generative AI to outsmart one of the greatest medical threats of our time — antibiotic resistance.

🔬 Instead of searching traditional chemical libraries, the team generated over 36 million hypothetical molecules and screened them using graph neural networks, which analyze atoms and bonds as interconnected graphs.

⚡ Key results:
• 24 molecules were selected and synthesized
• 7 showed strong antibacterial activity
• 2 proved so effective they cured infected mice

🧪 The top candidates are NG1 and DN1:
• DN1 successfully eliminated MRSA skin infections in mice
• NG1 wiped out drug-resistant gonorrhea

💡 What makes this breakthrough unique is how AI opens entirely new “chemical space,” beyond the reach of existing catalogs — giving scientists a way to discover novel compounds faster and more cost-effectively.

MIT researchers believe this approach could spark a “second golden age of antibiotics.”

📌 Read more: MIT News

@Science #AI #Biotech #Antibiotics #DrugResistance

🧬 AI just made proteins that can turn back cellular aging 50× faster

OpenAI created proteins that rejuvenate cells 50× more effectively

OpenAI, together with Retro Biosciences, developed a new model — GPT-4b micro — designed for protein engineering.

The model helped create new variants of the Yamanaka factors — proteins that turn ordinary cells into stem cells.

Result: a 50-fold improvement in reprogramming efficiency compared to natural proteins.

The new proteins, RetroSOX and RetroKLF, differed from the originals by over 100 amino acids, yet worked better in 30–50% of cases.

Most importantly — they showed improved ability to repair DNA damage, which is directly linked to cellular rejuvenation.

In experiments on human fibroblasts from donors over 50, within just 7 days more than 30% of cells began expressing pluripotency markers.

Forget Ozempic. In a couple of years, we might be injecting lifespan extensions instead.
Like in the movie In Time.
Let’s just hope it doesn’t end like The Substance. :)

#OpenAI #Longevity #Biotech

@science

Imagine your liver biopsy being scored not by a panel of pathologists, but by an AI that regulators officially treat as a “lab tool” for drug trials. That just became real.

PathAI has announced that its AIM-MASH AI Assist system is the first AI-powered pathology tool ever qualified by the US FDA (and already by the European Medicines Agency) for use in clinical trials of MASH — a common, fatty liver disease that can progress to cirrhosis and cancer. Instead of three experts arguing over how bad the damage looks on a slide, the model helps a single pathologist assign consistent scores.

Why this matters: drug trials for liver disease live and die on tiny changes in biopsy scores. Human reads are slow, expensive and notoriously variable. An AI that gives the same answer every time for the same slide can make trials faster, cheaper and statistically cleaner — which may mean more liver drugs actually making it to market.

Important caveat: this AI is cleared only as a biomarker tool for trials, not for diagnosing individual patients. But if regulators are starting to trust models as part of the evidence pipeline, how long until similar systems sit inside routine hospital workflows?

Would you be comfortable knowing an AI scored your tissue sample in a drug trial? Should this kind of model stay in research, or gradually move into everyday diagnostics?

Full story from PathAI’s press release: https://www.pathai.com/news/pathais-aim-mash-ai-assist-becomes-first-ai-powered-pathology-tool-to-receive-fda-qualification-for-mash-clinical-trials

#AI #medicine #pathology #liverdisease #clinicaltrials #FDA #biotech

🧬
DeepMind has released AlphaFold 4, pushing protein structure prediction into a new era.

The updated model handles:
• ~20,000 human proteins
• multi-chain complexes
• protein–protein interactions
• selected post-translational modifications

Reported accuracy reaches ~98% on benchmark datasets — approaching experimental resolution in many cases.

📄 Preprint (updated Feb 18, 2026):
https://arxiv.org/abs/2402.18567

⸻

🧪 Why this matters

This is no longer just about predicting isolated protein folds.

AlphaFold 4 moves toward modeling biological systems — complexes, assemblies, interaction interfaces — the level where real drug discovery happens.

Targets long considered “undruggable,” such as:

• KRAS
• MYC

may become structurally tractable thanks to improved interface prediction.

Pharma companies are already integrating AI-generated structures into drug pipelines, potentially shortening early-stage discovery timelines dramatically. (Not “10 years → 2 years” overnight — but the structural bottleneck is shrinking fast.)

⸻

🔬 Bigger picture

If AlphaFold 2 solved the protein folding problem,
AlphaFold 4 begins solving the interaction problem.

Structural biology is shifting from slow, expensive crystallography toward AI-assisted molecular design.

We are watching the transition from “map the molecule” to “engineer the molecule.”

The question now isn’t can we predict structure?
It’s how fast can we turn structure into therapy?

#AlphaFold #AI #DrugDiscovery #Biotech #ComputationalBiology

🧬 Scientists May Have Reactivated a Dormant Regeneration Program in Mammals

For a long time, scientists believed that mammals simply lost the ability to regenerate complex body parts during evolution. Salamanders can regrow entire limbs. Mammals usually heal injuries with scar tissue.

But researchers at Texas A&M University have now demonstrated that this regenerative potential may still exist — just in a dormant state.

In a new study published in Nature Communications, the team led by Dr. Ken Muneoka used a two-step treatment that redirected healing away from scar formation and toward actual tissue regeneration. In animal models, amputated digits regrew key structures including bone, tendons, ligaments, and joint tissues — components that mammals normally cannot rebuild once lost.

The approach relies on two growth factors applied in sequence:

• FGF2 (fibroblast growth factor 2) first stimulates the formation of a blastema — a specialized cluster of regenerative cells normally seen in animals such as salamanders.

• Several days later, BMP2 (bone morphogenetic protein 2) provides instructions that guide those cells to rebuild specific tissues.

Key findings:

🔹 Regeneration occurred without transplanting stem cells — the body’s own cells were reprogrammed locally

🔹 Bone, tendon, ligament, and joint structures regenerated after amputation

🔹 Cells could be instructed to form tissues in locations where they would not normally develop

🔹 BMP2 is already FDA-approved for certain medical applications, while FGF2 has undergone extensive clinical investigation

🔹 The regenerated structures were not perfect replicas, but major functional components were restored

Important caveat: these results come from animal studies, not human clinical trials. Whether the same strategy can trigger comparable regeneration in humans remains unknown.

Still, the work suggests that mammalian regeneration may not have disappeared during evolution. Instead, the underlying biological program may still be present — but normally remains switched off.

If that turns out to be true, future regenerative therapies may focus less on adding new cells and more on activating capabilities our bodies already possess.
📄 Original paper (Nature Communications) · ScienceDaily

#RegenerativeMedicine #Biotech #TissueEngineering #NatureCommunications #FutureOfMedicine #science

🧬 Scientists May Have Found a New Way to Mass-Produce Cancer-Fighting Immune Cells

For more than a decade, cancer immunotherapy has been dominated by T cells. CAR-T therapies can be powerful against some blood cancers, but they remain expensive, highly personalized, and much harder to use against solid tumors.

Now researchers at USC Stem Cell have shifted attention to a different immune lineage: granulocyte-monocyte progenitors, or GMPs — early precursor cells that can produce macrophages, the immune system’s “first responders.”

Macrophages are especially interesting because they naturally enter tumors, engulf abnormal cells, and help coordinate immune responses. But mature macrophages are difficult to grow in large numbers, hard to genetically engineer, and not ideal for freezing and storage.

The USC team worked one step earlier — with GMPs before they mature. Using a defined chemical cocktail, they managed to keep mouse and human GMPs in a progenitor-like state while allowing them to expand long-term in the lab. That is important because long-term self-renewal in the blood system was traditionally associated mainly with true hematopoietic stem cells, not more committed progenitors.

Then the researchers engineered these GMPs with CAR receptors so they could recognize cancer cells. They also added a CAR-Fc design that can recruit other immune cells and help activate broader anti-tumor responses.

In mouse experiments, the engineered GMPs settled into bone marrow and other blood-forming tissues, where they continuously generated tumor-infiltrating macrophages and other myeloid cells. The cells suppressed CD19-positive leukemia and HER2-positive solid tumors, and the dual CAR-Fc design showed stronger effects in allogeneic cancer models.

The same platform also restored antibacterial defense in mice with chronic granulomatous disease, an inherited immune deficiency disorder.

Why this matters: this is not just another CAR-T variant. It is a possible manufacturing breakthrough for an entirely different branch of the immune system — one that may be better suited for solid tumors and potentially easier to produce as an off-the-shelf therapy.

The important caveat: these are still preclinical results in mice. The real test will be whether the platform is safe, durable, and effective in humans.

But the idea is powerful: instead of only engineering mature immune cells, scientists may be learning how to grow a renewable upstream factory that keeps producing cancer-fighting cells from inside the body.

Paper: Cell
https://www.cell.com/cell/fulltext/S0092-8674(26)00643-4

Summary: ScienceDaily
https://www.sciencedaily.com/releases/2026/06/260620100317.htm

#Immunotherapy #Cancer #StemCells #CellTherapy #Biotech

🦴 A Single Injection Reversed Osteoarthritis in Animals — Human Trials Could Be Next

Osteoarthritis affects roughly one in six people over 30 worldwide. It slowly destroys cartilage — the smooth tissue that keeps bones from grinding against each other — and can eventually damage the bone underneath. Today, most treatments still focus on managing pain, reducing inflammation, or replacing the joint when damage becomes severe.

A Colorado research team is trying to change that.

Scientists from CU Boulder, CU Anschutz, and Colorado State University have developed two experimental regenerative therapies designed not just to relieve symptoms, but to push damaged joints to repair themselves.

The first approach repurposes an existing FDA-approved drug and delivers it through a patented particle system injected directly into the joint. Instead of releasing everything at once, the particles provide therapeutic bursts over several months.

The second is more like a biological repair kit: a cocktail of engineered proteins injected arthroscopically, where it hardens in place and recruits the body’s own progenitor cells to patch defects in cartilage and bone.

The early results are striking. In animal studies, a single injection restored arthritic and injured joints to a healthy state within four to eight weeks. The biomaterial patch produced what lead researcher Stephanie Bryant described as “full regeneration and repair of the defect.” The therapies also showed regenerative effects in human cells taken from patients undergoing joint replacement surgery.

ARPA-H has now advanced the project into its next phase, backed by up to $33.5 million under its NITRO program. A new company, Renovare Therapeutics, has also been formed to move the technology toward commercialization. If the next studies go according to plan, first human trials could begin within about 18 months.

The caveat is important: this is not a treatment available to patients yet. The strongest results so far come from animal models and lab-tested human cells, and the animal findings are still expected to be published in a peer-reviewed journal. Safety, dosing, durability, and real clinical benefit in people all remain to be proven.

But the direction is fascinating.

For hundreds of millions of people with osteoarthritis, the current choice is often painfully limited: manage symptoms for years, or eventually replace the joint. A minimally invasive therapy that tells the body to rebuild cartilage and bone would be a major shift — from pain control to true regeneration.

The big takeaway: the future of chronic joint disease may not be better painkillers. It may be teaching the body how to repair itself again.

📄📄 CU Boulder article: https://www.colorado.edu/today/2026/04/06/simple-shot-shows-promise-reverse-osteoarthritis-within-weeks
📰 ScienceDaily summary: https://www.sciencedaily.com/releases/2026/06/260619101356.htm



#Osteoarthritis #RegenerativeMedicine #Arthritis #Biotech #MedicalScience

🐸 A Frog Gut Bacterium Eliminated Colorectal Tumors in Mice

A bacterium found in the gut of Japanese tree frogs has shown a striking anti-cancer effect in mice.

Researchers at the Japan Advanced Institute of Science and Technology (JAIST) screened 45 bacterial strains isolated from amphibians and reptiles, including Japanese tree frogs, fire belly newts, and grass lizards. One strain stood out: Ewingella americana, a naturally occurring bacterium from the intestines of the Japanese tree frog.

In a mouse model of colorectal cancer, a single intravenous dose of E. americana led to complete tumor elimination in all treated mice — a 100% complete response rate in that experiment.

The bacterium appears to work in two ways.

First, it accumulates inside tumors, where oxygen levels are low and blood vessels are unusually leaky. Once there, the bacterial population increased by roughly 3,000 times within 24 hours, directly damaging cancer cells.

Second, it seems to wake up the immune system. The treatment attracted T cells, B cells, and neutrophils into the tumor and boosted inflammatory signals such as TNF-α and IFN-γ, helping the body attack the cancer more aggressively.

The safety data in mice were also encouraging. The bacteria disappeared from the bloodstream within 24 hours, did not colonize healthy organs such as the liver, spleen, lungs, kidneys, or heart, and caused only temporary mild inflammation. Over a 60-day observation period, the researchers reported no chronic toxicity.

But the caveat is essential: this is still mouse research.

Many cancer therapies look spectacular in preclinical models and fail later in humans. A living bacterium injected into the bloodstream would face a much higher safety bar in people, and the human immune response could be very different.

Still, the study is an unusually strong proof of concept for bacterial cancer therapy. Instead of simply changing the gut microbiome, the researchers used a living bacterium as a tumor-targeting agent — one that both attacks cancer cells and recruits the immune system.

The big takeaway: one of the next ideas in cancer therapy may come not from a synthetic drug library, but from the gut of a frog.

Original paper, Gut Microbes:
https://www.tandfonline.com/doi/full/10.1080/19490976.2025.2599562

DOI:
https://doi.org/10.1080/19490976.2025.2599562

ScienceDaily summary:
https://www.sciencedaily.com/releases/2026/07/260709160655.htm

JAIST press release:
https://www.jaist.ac.jp/english/whatsnew/press/2025/12/17-1.html

#CancerResearch #Microbiome #Immunotherapy #Biotech